The Company

About Us

Astrego is a rapidly growing in vitro diagnostic company based in Uppsala, Sweden. After a decade of fundamental research, the company was founded in March 2017 with the mission to help in the global fight against antimicrobial resistance (AMR).

The company name comes from Antibiotic Susceptibility Testing – AST, and rego – being latin for guide, steer or manage. Our products are designed to guide physicians in the selection of effective antibiotic treatments to improve patient outcomes and make antibiotic stewardship easy.

Our team combines multidisciplinary scientific excellence with seasoned entrepreneurs and diagnostic industry management.

About Us

Astrego is founded on technology originally developed for fundamental research on bacterial growth at the level of single cells (1) and sensitive bacterial imaging (2,3). It was however realized that this technology, in its simplest form, also had the potential to be used for very fast antibiotic susceptibility testing (4).

In Astrego this mission has been taken on by a dedicated team of experienced engineers with the necessary competences to transform this unique technology into diagnostic products that will be disruptive for clinical microbiology and make antibiotic stewardship easy.

1. Wallden et al. Cell 20172. Hammar et al. Science 20123. Hammar et al. Nature Genetics 2014, 4. Baltekin et al. PNAS 2017

About Us

Astrego is founded on technology originally developed for fundamental research on bacterial growth at the level of single cells (1) and sensitive bacterial imaging (2,3). It was however realized that this technology, in its simplest form, also had the potential to be used for very fast antibiotic susceptibility testing (4).

In Astrego this mission has been taken on by a dedicated team of experienced engineers with the necessary competences to transform this unique technology into diagnostic products that will be disruptive for clinical microbiology and make antibiotic stewardship easy.

1. Wallden et al. Cell 20172. Hammar et al. Science 20123. Hammar et al. Nature Genetics 2014, 4. Baltekin et al. PNAS 2017

News

  • The PNAS paper describing the Astrego technology is extensively discussed in the latest issue of the ASM Podcast: “This Week in Microbiology”.
    2018-08-09
  • Astrego has been granted a US patent on the core technology (U.S. pat.no. 10,041,104).
    2018-08-07
  • Astrego presents at “The 14th International Congress of the European Association for Veterinary Pharmacology and Toxicology 2018”, Wroclaw, Poland.
    2018-06-25
  • Astrego receive SEK 1 million to support clinical evaluation of the qUTI-system in collaboration with the Dept. of Infectious Disease at Akademiska University Hospital, Uppsala, Sweden. The grant is given within the call “Projekt för bättre hälsa” funded by Medtech4Health and the Swelife program.
    2018-05-18
  • 77Elektronika deliver first industrialized prototypes of the qUTI instrument.
    2018-02-18
  • Astrego presents at the AACC Conference “Emerging Clinical & Laboratory Diagnostics in the Healthcare Ecosysytem”, San Diego, USA.
    2017-10-31
  • Professor Elf is interviewed in The Pathologist about Astrego´s technology.
    December 2017
  • Astrego’s core paper is reviewed in JAMA.
    2017-10-10
  • Astrego´s core paper is selected as the Editor´s choice in Science Translational Medicine.
    2017-09-06
  • Astrego & 77Elektronika Kft enter collaboration for development of the qUTI instrument. 77Elektronika is a Hungarian-based market leading manufacturer of in vitro diagnostic urine analysis and urine sediment devices.
    2017-08-25
  • Astrego´s core paper is published in PNAS.
    2017-08-08
  • Astrego receive a “Seal of Excellence”from the H2020 SME Instrument for our Phase 1 application and SEK 0.5 million from Vinnova to perform market studies and prepare a business plan for the qUTI system.
    2017-05-03
  • Astrego Diagnostics AB is founded by management and a team of independent investors
    2017-03-28

Management

Ove Öhman, CEO

 

Özden Baltekin, CSO

  • Technology inventor & Explorative research

Mike Read PhD, COO

  • Program management & Operations

Mikael Olsson, CTO

  • Disposable cartridge development & Manufacturing

Elias Amselem PhD, Senior Scientist

  • Instrument development

Petter Hammar PhD, Senior Scientist

  • Assay development & Clinical research

Martin Lovmar PhD, VP Business Development

  • Partnering & IP management

Board

Sven Holmlund, Chairman

  • Business leader & independent investor

Johan Elf

  • Technology inventor & Scientific front-runner

Ernst Westman

  • IVD entrepreneur & Independent investor

Johan Winnerblad

  • Top-ranked M&A lawyer

Location

Astrego Diagnostics is located in Uppsala Sweden, a city with long history of fostering successful collaboration between Uppsala University and the local Bio- and Medtech industry. Success stories include Pharmacia (now GE Healthcare and Pfizer), Biacore (part of GE Healthcare), Phadia (part of Thermo Fisher), Åmic (now part of J&J), Q-med (now Galderma) and Pyrosequencing (out licensing to Illumina).

Contact

Ove Öhman, CEO

Email

info@astrego.se

Adress

Vallvägen 4B
SE-756 51 UPPSALA
Sweden